Amrutanjan Healt announces a new order win
TL;DR
What is the incremental production capacity added by the new Telangana facility for the 'Comfy' sanitary napkin brand, and how does this expansion alter the company's total installed capacity for the hygiene segment compared to the previous fiscal year?
Specific production capacity metrics for the new Telangana facility and total installed capacity figures for the 'Comfy' sanitary napkin brand are not separately disclosed in the available company filings or structured financial data.
While physical capacity units are omitted, financial disclosures show a substantial scale-up in manufacturing infrastructure and capital deployment:
- Capital Expenditure: Capex rose to Rs 55.00 Crores in FY26, up from Rs 35.55 Crores in FY25 and Rs 6.72 Crores in FY24 [1].
- Capital Work-in-Progress (CWIP): CWIP surged to Rs 105.48 Crores at the end of FY26 compared to Rs 16.20 Crores in FY25 and Rs 2.34 Crores in FY24 [2], reflecting heavy facility construction and commissioning activity.
- Fixed Assets: Total fixed assets expanded to Rs 156.74 Crores in FY26 from Rs 65.61 Crores in FY25 [3], consistent with major plant additions.
What was the total capital expenditure (Capex) allocated to this Telangana facility, and how has this outflow been reflected in the company's cash flow statement or debt position in the most recent quarterly filings?
Specific capital expenditure allocated to the Telangana facility is not separately disclosed in the company's structured financial data or filings context.
Broad capital expenditure, cash flow, and debt metrics for Amrutanjan as of the most recent reported period (Q4 FY26 standalone) reflect the following:
- Capital Outlays and CWIP: TTM Capex was reported at Rs 55.00 Crores [4]. Capital Work in Progress (CWIP) expanded significantly to Rs 105.48 Crores in Q4 FY26 [5] from Rs 26.41 Crores in Q2 FY26 [5], reflecting ongoing facility construction or asset expansion. Total fixed assets stood at Rs 156.74 Crores [6].
- Cash Flow Statement Impact: TTM cash flow from investing activities was -Rs 21.23 Crores [7], funded comfortably by TTM operating cash flow of Rs 35.97 Crores [8]. Financing cash flow outflow was -Rs 13.62 Crores [9], culminating in a TTM net cash flow of Rs 1.12 Crores [10].
- Debt Position: The company remains debt-free, with total debt at Rs 0.00 Crores [11] and current borrowings at Rs 0.00 Crores [12]. Net debt stood at -Rs 11.27 Crores [13], supported by cash and equivalents of Rs 11.27 Crores [14].
Limits: Facility-wise or project-specific capex breakdowns are not reported in the available disclosures, preventing a direct quantification of the Telangana plant allocation.
How does the commissioning of this facility align with the company's stated strategy for the 'Comfy' brand, and what is the current revenue contribution of the hygiene segment relative to the core pain management business as per the latest segment reporting?
Standalone Performance Overview
Amrutanjan Health Care Limited reported Q4 FY26 standalone revenue of Rs 149.77 Crores [15] (up 10.60% YoY [16]), bringing full-year FY26 standalone revenue to Rs 502.56 Crores [17]. Standalone EBITDA for Q4 FY26 reached Rs 30.28 Crores [18] (up 34.50% YoY [19]), yielding a quarterly EBITDA margin of 20.22% (derived from Rs 30.28 Crores EBITDA [18] and Rs 149.77 Crores revenue [15]).
However, qualitative disclosures detailing facility commissioning, capital expenditure allocation, and alignment with the long-term strategic roadmap for the 'Comfy' sanitary napkin brand were not reported in the Q4 FY26 financial results. Furthermore, a discrete revenue breakdown separating the hygiene segment (Comfy) from the core pain management business was not included in the standalone segment reporting up to Q4 FY26.
---
Financial Tracking Summary
The table below summarizes Amrutanjan's standalone operational performance across FY26 quarters:
- Notes: † Derived metric calculated as (EBITDA / Revenue) x 100.*
---
Disclosure Limits & Segment Visibility
- 'Comfy' Brand Strategic Alignment: Detailed qualitative commentary regarding new facility commissioning, operational capacity expansion, and in-house manufacturing transitions for the 'Comfy' brand was not disclosed in the reported financial releases for FY26.
- Hygiene vs. Pain Management Segment Split: Discrete segment-wise revenue contribution and operating profit metrics for hygiene (Comfy) relative to core pain management (Balms, Roll-ons, Joint Care) were not separately broken down in the reported quarterly disclosures.*
| Metric | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | FY26 TTM | Basis / Source |
|---|---|---|---|---|---|---|
| Revenue (Rs Cr) | 94.05 | 117.70 | 141.04 | 149.77 | 502.56 | Standalone actuals [15], [17] |
| YoY Revenue Growth (%) | 12.30% | 7.10% | 14.90% | 10.60% | — | Reported YoY [16] |
| EBITDA (Rs Cr) | 12.87 | 20.82 | 29.29 | 30.28 | 93.26 | Standalone actuals [18], [20] |
| EBITDA Margin (%) | 13.68%† | 17.69%† | 20.77%† | 20.22%† | 18.56%† | Derived from revenue and EBITDA [15], [18] |
| PAT (Rs Cr) | 8.31 | 13.96 | 19.45 | 16.19 | 57.91 | Standalone actuals [21], [22] |
Sources
- [1]TTM Capex
- [2]Capital Work in Progress
- [3]Fixed Assets
- [4]TTM Capex
- [5]Capital Work in Progress
- [6]Fixed Assets
- [7]TTM Cash Flow from Investing
- [8]TTM Operating Cash Flow
- [9]TTM Cash Flow from Financing
- [10]TTM Net Cash Flow
- [11]Total Debt
- [12]Current Borrowings
- [13]Net Debt
- [14]Cash and Equivalents
- [15]Revenue INR
- [16]Revenue YoY
- [17]TTM Revenue INR
- [18]EBITDA
- [19]EBITDA YoY
- [20]TTM EBITDA
- [21]PAT
- [22]TTM PAT
Keep digging
